Vascular endothelial growth factor (VEGF) antibody significantly increases the risk of hand-foot skin reaction to multikinase inhibitors (MKIs): A systematic literature review and meta-analysis.
Vascular endothelial growth factor (VEGF) antibody significantly increases the risk of hand-foot skin reaction to multikinase inhibitors (MKIs): A systematic literature review and meta-analysis.
复制标题
血管内皮生长因子（VEGF）抗体显着增加手足皮肤对多激酶抑制剂（MKI）反应的风险：系统文献综述和荟萃分析
DOI：
10.1111/1440-1681.12935
复制
发表时间：
2018-07
影响因子：
2.9
通讯作者：
He Q
中科院分区：
文献类型：
--
作者：
Zhu Y;Zhang X;Lou X;Chen M;Luo P;He Q
近年来，随着多激酶抑制剂（MKI）的出现，皮肤毒性如手足皮肤反应（HFSR）是主要的副作用，并且缺乏有效的预测方法。在此，我们通过对接受MKI和抗血管内皮生长因子抗体治疗的患者发生HFSR的风险进行Meta分析，更新了既往的系统性综述。检索了截至2015年2月5日的PubMed出版物和美国临床肿瘤学会年会上提交的摘要，以识别相关研究，并纳入了9项试验中的236例转移性肿瘤患者进行分析。在Meta分析中，接受联合治疗的患者中，所有级别和高级别HFSR的汇总发生率分别为56.9% [95%置信区间（CI），45%-71.1%]和14.3%（95% CI，9%-24.2%），与MKI单药治疗相比观察到显著差异（P <0.05）。进一步的亚组分析表明，增加贝伐珠单抗（77.8% vs 51.1%，P = 0.04）和MKI（64.3% vs 52.6%，P = 0.02）的剂量可显著增加HFSR的发生率。此外，联合化疗对HFSR风险的影响最小（61% vs 55.3%，P = .5）。本次更新的审查和Meta分析证实了使用MKI和抗血管内皮生长因子抗体导致HFSR发生率风险增加。因此，使用这些疗法需要安全标准。
With the use of multikinase inhibitors (MKIs) having emerged in recent years, skin toxicities such as hand–foot skin reaction (HFSR) are primary side effects, and they lack effective prediction methods. Here, we updated a previous systematic review by establishing a meta‐analysis of the risk of developing HFSR among patients receiving MKIs and antivascular endothelial growth factor antibody. Publications from PubMed and abstracts presented at the American Society of Clinical Oncology Annual Meeting up to February 5, 2015, were searched to identify relevant studies, and a total of 236 patients with metastatic tumours in nine trials were included for analysis. In the meta‐analysis, the pooled incidence rates of all‐grade and high‐grade HFSR among patients who received the combination therapy were 56.9% [95% confidence interval (CI), 45%‐71.1%] and 14.3% (95% CI, 9%‐24.2%), respectively, with significant differences observed with MKI monotherapy (P < .05). Further subgroup analysis demonstrated that increasing the dosages of bevacizumab (77.8% vs 51.1%, P = .04) and MKIs (64.3% vs 52.6%, P = .02) significantly increased HFSR incidence. Moreover, combination with chemotherapy exerted a minimal effect on HFSR risk (61% vs 55.3%, P = .5). This updated review and meta‐analysis confirm the increased risk of HFSR incidence due to the use of MKIs and antivascular endothelial growth factor antibody. Thus, using these therapies requires safety standards.
登录
查看更多内容
影响因子：
3.1
作者：
Breccia, M;Carmosino, I;Alimena, G
通讯作者：
Alimena, G
影响因子：
3
作者：
Mahalingam, Devalingam;Malik, Laeeq;Sarantopoulos, John
通讯作者：
Sarantopoulos, John
DOI：
10.1016/0197-2456(86)90046-2
发表时间：
1986-09-01
期刊：
CONTROLLED CLINICAL TRIALS
影响因子：
--
作者：
DERSIMONIAN, R;LAIRD, N
通讯作者：
LAIRD, N
DOI：
10.1158/1078-0432.ccr-13-0708
发表时间：
2013-09-01
期刊：
Clinical cancer research : an official journal of the American Association for Cancer Research
影响因子：
--
作者：
Galanis E;Anderson SK;Lafky JM;Uhm JH;Giannini C;Kumar SK;Kimlinger TK;Northfelt DW;Flynn PJ;Jaeckle KA;Kaufmann TJ;Buckner JC
通讯作者：
Buckner JC
影响因子：
5.8
作者：
Gridelli, Cesare;Maione, Paolo;Rossi, Antonio
通讯作者：
Rossi, Antonio